血浆置换在抗MDA5阳性皮肌炎合并间质性肺病联合免疫抑制治疗中的疗效
进展组中8例行血浆置换,5例存活,而未行PE的5例均死亡(P=0.04)。基线中性粒细胞淋巴细胞比值、铁蛋白、低氧血症、HRCT评分及治疗4周内KL-6升高是疾病进展的预后因素。
要点
- 血浆置换可能是抗MDA5阳性DM合并快速进展性间质性肺病的有效辅助治疗。
- 进展组中行PE者5/8存活,未行PE者5/5死亡,差异有统计学意义(P=0.04)。
- 基线NLR、铁蛋白、低氧血症、HRCT评分及4周内KL-6升高可预测难治病例。
核心结论
- 血浆置换应作为抗MDA5阳性DM合并RP-ILD的有效辅助治疗。
- 评估基线实验室检查、单核/巨噬细胞来源细胞因子及KL-6升高、HRCT评分和低氧血症有助于预测难治病例并早期决定是否行PE。
研究设计与样本
- 根据是否出现呼吸功能恶化分为两组:未进展组(A组,n=25)和进展至低氧血症组(B组,n=13)。
- 治疗前采用多重检测法评估血清细胞因子。
主要发现
- B组中8例接受PE,5例存活;未接受PE的5例均死亡(P=0.04)。
- A组无一例接受PE。
- 基线中性粒细胞淋巴细胞比值升高、血清铁蛋白升高、低氧血症、HRCT评分高及治疗前4周内KL-6升高是疾病进展的预后因素。
- B组血清IL-1、IL-6、IL-8、IL-10、IL-12p70、IL-18和sCD163水平高于A组。
关键数值与推荐
- PE在B组8例中实施,5例存活;未实施PE的5例均死亡(P=0.04)。
- 预后因素包括:中性粒细胞淋巴细胞比值升高、血清铁蛋白升高、低氧血症、HRCT评分高、治疗前4周内KL-6升高。
- B组血清IL-1、IL-6、IL-8、IL-10、IL-12p70、IL-18和sCD163水平高于A组。
临床怎么用
- 对接受联合免疫抑制治疗的抗MDA5阳性DM-ILD患者,应评估基线NLR、铁蛋白、低氧血症、HRCT评分及细胞因子水平。
- 治疗4周内监测KL-6升高,有助于早期识别难治病例并及时考虑血浆置换。
局限性
- 原文未报告PE的具体方案、治疗时机及长期随访结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Rapidly progressive interstitial lung disease (RP-ILD) with poor prognosis often accompanies anti-melanoma differentiation-associated gene 5 (MDA5)-positive DM. Combined immunosuppressive therapy, including glucocorticoids, calcineurin inhibitors and intravenous cyclophosphamide (IVCY) is reportedly effective in DM with RP-ILD, but some patients remain resistant to therapy. We examined the utility of plasma exchange (PE) in such intractable cases and investigated the prognostic factors of the disease. METHODS: Thirty-eight anti-MDA5-positive DM-ILD patients who received the combined immunosuppressive therapy were retrospectively reviewed. Their serum cytokines were evaluated by multiplex assay before treatment. The patients were divided into two groups: those who achieved remission without exacerbation of respiratory dysfunction (n = 25, group A) and those who progressed to hypoxemia during the treatment (n = 13, group B). RESULTS: PE was carried out in eight group B patients, but none of group A. Five of the eight treated with PE survived, while the five untreated patients died (P =0.04). Higher neutrophil lymphocyte ratio, higher serum ferritin, hypoxemia, high-resolution computed tomography (HRCT) score before treatment and increase of Krebs von Lungen-6 (KL-6) in the first 4 weeks of the treatment were the prognostic factors for disease progression. Serum cytokines such as IL-1, IL-6, IL-8, IL-10, IL-12p70, IL-18 and sCD163 levels were higher in group B than group A. CONCLUSION: PE should be an effective adjuvant treatment in anti-MDA5-positive DM with RP-ILD. Assessment of basal laboratory tests or monocyte/macrophage-derived cytokines and the increase of KL-6, HRCT score and hypoxemia may help us to predict intractable cases and to make early treatment decisions regarding PE in anti-MDA5-positive DM.
引用
- Shirakashi M, Nakashima R, Tsuji H, et al. Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment. Rheumatology (Oxford). 2020. PMID: 32276271. doi:10.1093/rheumatology/keaa123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。